Hepatocellular carcinoma, the most common primary liver malignancy, poses a significant global health challenge as the sixth most incident cancer and the third leading cause of cancer-related mortality worldwide. Despite advances in locoregional therapies and systemic treatments, a substantial subset of HCC patients progresses to unresectable disease, underscoring the urgent need for effective systemic options. Immunotherapy has recently reshaped the oncological landscape in this setting, with atezolizumab—a monoclonal antibody targeting PD-L1—combined with bevacizumab, an anti-VEGF monoclonal antibody, becoming the first-line standard of care after the IMbrave150 trial demonstrated improved overall and progression-free survival.

The Indian study, retrospectively analyzing data from 104 patients treated from September 2020 to May 2024, offers the first comprehensive evaluation of this combination therapy within the Indian demographic and healthcare context. With a median patient age of 67 years, the cohort presents a realistic portrait of advanced HCC patients encountered in routine practice, including a wide spectrum of liver function statuses classified by the Child-Pugh scoring system.

Notably, the majority of patients (74%) had compensated cirrhosis (Child-Pugh A), but a significant proportion presented with more advanced hepatic insufficiency—18% were Child-Pugh B and 3% Child-Pugh C—highlighting a key divergence from the stringent inclusion criteria of the IMbrave150 trial that primarily enrolled Child-Pugh A patients. This heterogeneity underscores the complexity of translating clinical trial findings into real-world settings, where comorbidities and liver dysfunction often complicate therapeutic administration and outcomes.

Administered intravenously every three weeks as per the IMbrave150 protocol, atezolizumab dosing was standardized at 1200 mg, while bevacizumab was dosed at 15 mg/kg. The retrospective design leveraged detailed records capturing demographics, treatment-related adverse events, and radiological responses, facilitating a nuanced assessment of safety and efficacy.

The study’s findings reveal a median overall survival (OS) of 14.8 months (95% confidence interval [CI]: 6.8–22.9) with a corresponding median progression-free survival (PFS) of 6.2 months (95% CI: 2.5–9.9). These figures, while slightly lower than the landmark IMbrave150 trial outcomes, remain clinically significant, especially given the inclusion of patients with more advanced liver dysfunction. The reduced survival metrics likely reflect the broader eligibility criteria employed in routine clinical practice and the consequent increased frailty of the patient cohort.

Safety analyses demonstrated that the combination therapy maintains an acceptable toxicity profile in this real-world population. Adverse events were manageable, enabling continuation of treatment in most cases, though the study does not specify detailed rates of individual toxicities. These safety data bolster the argument for broader application of atezolizumab-bevacizumab in unresectable HCC beyond the strictly regulated confines of randomized trials.

This study also sheds light on potential challenges faced by clinicians treating HCC in India, including the prevalence of advanced cirrhosis at diagnosis and resource constraints impacting continuous monitoring and management of treatment-emergent effects. The authors underscore the need for individualized risk-benefit analyses to optimize outcomes in patients who may traditionally be deemed ineligible for immunotherapy.

The broader implications of this study resonate with the global oncology community’s ongoing efforts to refine patient selection for immunotherapy regimens. Incorporating patients with varying degrees of liver dysfunction may help delineate subgroups that derive the most benefit from atezolizumab-bevacizumab, while also identifying those at greater risk of adverse outcomes. Such stratification is vital for tailoring therapies in real-world settings that often differ markedly from trial populations.

Moreover, the multicentric nature of the study enhances the generalizability of its findings, reflecting diverse clinical practices and patient characteristics across healthcare facilities. This diversity is crucial in ensuring that immunotherapy strategies are both effective and feasible on a population scale, encompassing geographic, genetic, and socioeconomic variations.

While retrospective in nature, this research lays essential groundwork for future prospective studies that could integrate biomarkers of response, refine dosing strategies, and explore combination regimens that may further improve outcomes. The emerging data on atezolizumab-bevacizumab in diverse populations reinforce the transformative potential of immune checkpoint inhibitors enhanced by anti-angiogenic therapy in HCC.

In conclusion, this Indian multicentric study affirms that atezolizumab combined with bevacizumab is a viable and tolerable treatment option for patients with unresectable hepatocellular carcinoma, including those with compromised hepatic reserve. Despite slightly lower survival rates compared to controlled trials, the real-world efficacy and safety profiles highlight the regimen’s critical role in expanding therapeutic horizons for this difficult-to-treat malignancy.

As immunotherapy continues to evolve rapidly, integrating findings from varying populations and clinical contexts will be indispensable. The study’s results advocate for continued vigilance in managing toxicities and caution in extending treatment to patients with advanced cirrhosis, while also encouraging broadening access to these potentially life-prolonging therapies.

This multicentric Indian experience enriches the global understanding of immunotherapy application in HCC, providing a valuable reference point for oncologists grappling with the complexities of treating diverse and challenging patient populations in routine practice.

Through ongoing research and collaboration, the oncology community edges closer to achieving more personalized, effective, and accessible care for patients with hepatocellular carcinoma worldwide, illuminating a path forward against this formidable disease.

Subject of Research: Safety and efficacy of atezolizumab and bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma.

Article Title: Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study.

Article References:
Babu, M., Komaranchath, A.S., Valsan, A. et al. Safety and efficacy of atezolizumab/bevacizumab in unresectable hepatocellular carcinoma—a multicentric study. BMC Cancer 25, 1026 (2025). https://doi.org/10.1186/s12885-025-14400-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14400-9

Hepatocellular carcinoma remains a global health challenge due to its high mortality, often stemming from late diagnosis and the limited efficacy of conventional treatments in advanced stages. The advent of immunotherapy—specifically immune checkpoint inhibitors like atezolizumab, an anti-PD-L1 antibody, combined with bevacizumab, an anti-VEGF monoclonal antibody—has revolutionized treatment paradigms. These agents reinvigorate the patient’s immune system to target tumor cells, yet this immune activation can provoke adverse systemic effects collectively termed immune-related adverse events (irAEs). These adverse responses, while potentially severe, are incompletely characterized in Latin American populations, particularly within the multifaceted clinical contexts typical of everyday medical practice.

To address this knowledge gap, researchers conducted a multicentric retrospective cohort study encompassing 99 patients with advanced unresectable HCC treated between 2019 and 2024 across Argentina, Brazil, Chile, and Colombia. These patients received the atezolizumab and bevacizumab regimen under routine clinical care, providing invaluable real-world data. The median treatment duration was approximately six months, reflecting the typical clinical course for this demographic. Crucially, the investigators meticulously documented incidence rates, severity, and organ-specific manifestations of irAEs, as well as their relationship to overall survival outcomes.

Intriguingly, only 18% of the cohort experienced immune-mediated toxicities, a noticeably lower frequency compared to prior randomized clinical trials where irAE rates often exceed 30%. The predominant organ systems involved were the liver, manifesting as immune-mediated hepatitis, and the thyroid gland, causing thyroiditis. Most irAEs were graded as mild to moderate, corresponding to Common Terminology Criteria for Adverse Events (CTCAE) grades 1 or 2, and resolved rapidly within approximately 30 days following appropriate clinical intervention. Steroid therapy was required in just eight cases for immune suppression, underscoring that most irAEs were manageable without aggressive immunomodulation.

From a survival perspective, the study’s Kaplan-Meier analyses demonstrated no statistically significant difference in median overall survival between patients who developed irAEs and those who did not; both groups exhibited a median survival of 18.5 months. This finding challenges prior hypotheses suggesting that immune toxicities correlate with enhanced antitumor efficacy. Instead, it supports the clinical notion that irAEs, while necessitating vigilance, do not inherently negate the therapeutic benefits of atezolizumab and bevacizumab. Therefore, prompt recognition and tailored management of irAEs remain key to optimizing patient outcomes.

A particularly compelling aspect of this research was the identification of elevated baseline alpha-fetoprotein (AFP) levels—specifically values exceeding 400 ng/mL—as a significant predictor for the development of irAEs. AFP, a well-established biomarker linked to tumor burden and aggressiveness in HCC, may therefore serve as a valuable tool to stratify patients’ risk for immune toxicity. This predictive association empowers clinicians to implement intensified monitoring protocols or preemptive strategies in high-risk patients, potentially improving the safety profiles of immunotherapeutic regimens.

The study also highlights the distinct nature of real-world evidence compared to stringent clinical trial data. Trial participants often undergo rigorous monitoring and follow-up, with detailed recording of adverse events, which might inflate irAE incidence statistics relative to everyday clinical settings. Variability in patient demographics, comorbidities, and healthcare infrastructure across Latin America further contributes to heterogeneity in treatment responses and side-effect profiles. These factors underscore the importance of region-specific data to guide practical clinical decision-making and resource allocation.

Moreover, the researchers emphasize the dynamic interplay between immunotherapy and underlying liver disease. Many enrolled patients had cirrhosis or other chronic hepatic conditions that can complicate the immunological landscape, potentially masking or mimicking irAEs. This complexity necessitates nuanced clinical judgment to differentiate adverse events from disease progression or decompensation. The study’s findings advocate for multidisciplinary collaborations involving oncologists, hepatologists, and immunologists to optimize patient care.

From a mechanistic standpoint, the study reaffirms the dualistic nature of immunotherapy in cancer treatment. While agents like atezolizumab unleash cytotoxic T-cell responses to eradicate tumor cells, they can inadvertently disrupt immune tolerance, precipitating autoimmune-like toxicities. Bevacizumab’s anti-angiogenic effects add another layer, modulating tumor vasculature and potentially influencing immune cell trafficking. Understanding these interactions at a molecular level remains a crucial research frontier, with implications for designing next-generation therapies that maximize antitumor activity while minimizing collateral damage.

Importantly, the study contributes to the broader discourse on health disparities and the generalizability of clinical trial findings. Latin American countries often face challenges such as limited access to advanced therapeutics, variations in healthcare delivery, and underrepresentation in global studies. By focusing on this cohort, the authors provide data that acknowledges regional specificities, fostering equitable improvements in cancer care. This approach aligns with global initiatives promoting inclusivity and diversity in oncology research.

In conclusion, this landmark study elucidates the incidence, clinical characteristics, and prognostic implications of immune-mediated adverse events in Latin American patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. The findings underscore that while irAEs are relatively uncommon and generally manageable, their occurrence does not adversely impact overall survival. Elevated AFP emerges as a promising biomarker to identify individuals at higher risk for toxicity. These real-world insights reinforce the necessity for vigilant, individualized management to harness the full potential of immunotherapy in HCC, ultimately striving toward improved patient outcomes and quality of life.

Subject of Research: People

Article Title: Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma

News Publication Date: 19-May-2025

Web References:

• Oncotarget Volume 16: https://www.oncotarget.com/archive/v16/
• DOI link: http://dx.doi.org/10.18632/oncotarget.28721

Image Credits: Copyright: © 2025 da Fonseca et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

Keywords: liver cancer; immunotherapy; adverse events; immunology; real-world